3 articles for “ESBLs”

Set a search alert

Research ArticleOpen accessIn the keywordsSusceptibility and Detection of Extended Spectrum β-Lactamase Enzymes from Otitis Media PathogensEjikeugwu Chika, Iroha Ifeanyichukwu, Adikwu Michael, Esimone CharlesOtitis media is the bacterial infection of the middle ear usually accompanied with inflammation, effusions and pain. It can present clinically in two major forms: Acute Otitis Media (AOM) and Otitis Media with Effusion (OME) and it is one of the leading cause of hospital visits and antibiotic prescriptions amongst children and even adults. Antibiotic resistance is a global public … …American Journal of Infectious Diseases, Vol. 9, Issue 1 · 21 Mar 2013 · 7,970 accessesView PDF Cite

Research ArticleOpen accessIn the abstractAntimicrobial Pattern and Clonal Dissemination of Extended-Spectrum Beta-Lactamase Producing Klebsiella Spp IsolatesSobhan Ghafourian, Nourkhoda Sadeghifard, Zamberi bin Sekawi et al.Problem statement: Gram-negative pathogens harboring ESBLs have caused numerous outbreaks of infections and are becoming an increasing therapeutic problem in many countries. The incidence of ESBL-producing strains among clinical isolates has been steadily increasing over the past years resulting in limitations of therapeutic option. The focus of this study was to examine the molecular epidemiology of ESBL-producing Klebsiella spp, investigate … …American Journal of Infectious Diseases, Vol. 6, Issue 4 · 31 Dec 2010 · 7,898 accessesView PDF Cite

Research ArticleOpen accessIn the abstractPharmacodynamic Comparison of the Carbapenems Against E. coli and Klebsiella spp. Containing Extended spectrum β-lactamasesKathryn J. Eagye, Joseph L. Kuti, David P. NicolauCarbapenems are the treatment of choice for extended-spectrum β-lactamases (ESBLs). Ertapenem is a new member of the carbapenem class, and is often grouped with imipenem and meropenem as a recommended treatment for ESBLs. However, new in vitro data question ertapenem’s inclusion as a first line treatment for these bacteria, suggesting that ertapenem has a lower likelihood of obtaining appropriate pharmacodynamic … …American Journal of Infectious Diseases, Vol. 1, Issue 3 · 30 Sep 2005 · 6,886 accessesView PDF Cite